Stock listing

ASX:PTX Prescient Therapeutics Limited Share Price

Follow Prescient Therapeutics Limited into a list and get an email when it puts out news.

Share price · ASX:PTX

$0.055 AUD 0.000 (0.0%)

Close on Nov 20, 2026

Past year -6.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.055 – $0.057 AUDNov 20, 2026
Volume
259,599 sharesNov 20, 2026
Market cap
$62.91M AUDAt the close on Nov 20, 2026 · price × 1.14B shares outstanding
52-week range
$0.049 – $0.125 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$52,779 AUDMedian day 514,962 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Prescient Therapeutics Limited logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:PTX · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.0550.0000.0%$0.057$0.057$0.055259,599
$0.055-0.002-3.5%$0.056$0.057$0.05581,081
$0.057+0.001+1.8%$0.056$0.057$0.055420,330
$0.056-0.002-3.4%$0.058$0.060$0.056303,956
$0.058-0.005-7.9%$0.063$0.063$0.058112,889
$0.063+0.001+1.6%$0.064$0.065$0.0631,237,419
$0.062+0.002+3.3%$0.060$0.063$0.060575,214
$0.060+0.004+7.1%$0.056$0.061$0.056397,216
$0.056+0.002+3.7%$0.055$0.056$0.055264,067
$0.054+0.001+1.9%$0.054$0.055$0.054266,748
$0.053+0.002+3.9%$0.051$0.053$0.051149,755
$0.051-0.002-3.8%$0.054$0.054$0.051141,578
$0.053+0.003+6.0%$0.051$0.053$0.05149,214
$0.050-0.003-5.7%$0.052$0.052$0.050240,332
$0.053-0.002-3.6%$0.055$0.055$0.053191,792
$0.055+0.003+5.8%$0.052$0.055$0.05217,580
$0.052-0.002-3.7%$0.056$0.056$0.052457,731
$0.054+0.003+5.9%$0.053$0.054$0.052271,970
$0.051-0.003-5.6%$0.054$0.054$0.0501,589,874
$0.054-0.002-3.6%$0.053$0.055$0.052886,759
$0.056-0.001-1.8%$0.061$0.061$0.056312,032
$0.057-0.001-1.7%$0.061$0.061$0.057439,461
$0.058+0.003+5.5%$0.056$0.061$0.056189,701
$0.055-0.003-5.2%$0.057$0.057$0.054350,151
$0.058-0.003-4.9%$0.061$0.061$0.0561,086,998
$0.061-0.004-6.2%$0.066$0.066$0.0611,116,075
$0.0650.0000.0%$0.064$0.066$0.064350,979
$0.065+0.001+1.6%$0.065$0.065$0.064233,555
$0.064-0.002-3.0%$0.065$0.065$0.06432,637
$0.0660.0000.0%$0.066$0.066$0.064736,346
$0.066+0.001+1.5%$0.065$0.066$0.064501,512
$0.0650.0000.0%$0.065$0.065$0.065536,706
$0.065+0.001+1.6%$0.065$0.065$0.064489,319
$0.064-0.002-3.0%$0.066$0.066$0.064245,972
$0.0660.0000.0%$0.064$0.066$0.0641,346,125
$0.066-0.001-1.5%$0.067$0.067$0.0633,110,713
$0.067-0.005-6.9%$0.073$0.073$0.0671,574,217
$0.072+0.002+2.9%$0.072$0.073$0.0711,242,329
$0.070+0.002+2.9%$0.068$0.072$0.068532,870
$0.068+0.001+1.5%$0.066$0.068$0.066101,735
$0.0670.0000.0%$0.067$0.067$0.065291,715
$0.067-0.001-1.5%$0.068$0.068$0.0651,680,441
$0.0680.0000.0%$0.068$0.068$0.0680
$0.0680.0000.0%$0.068$0.068$0.0680
$0.068+0.001+1.5%$0.067$0.073$0.0673,477,311
$0.0670.0000.0%$0.067$0.068$0.067302,958
$0.067+0.001+1.5%$0.067$0.068$0.066598,310
$0.066+0.001+1.5%$0.065$0.069$0.0651,309,998
$0.065-0.003-4.4%$0.068$0.069$0.0651,367,985
$0.068+0.003+4.6%$0.066$0.069$0.0661,522,426
$0.0650.0000.0%$0.067$0.068$0.0641,584,896
$0.0650.0000.0%$0.067$0.069$0.0651,297,488
$0.065-0.003-4.4%$0.070$0.070$0.0651,080,892
$0.0680.0000.0%$0.068$0.071$0.0682,980,678
$0.068+0.001+1.5%$0.068$0.069$0.067528,412
$0.067-0.001-1.5%$0.068$0.068$0.066314,819
$0.0680.0000.0%$0.068$0.068$0.067832,037
$0.068+0.002+3.0%$0.067$0.068$0.066499,072
$0.066-0.001-1.5%$0.067$0.067$0.0641,296,592
$0.067-0.001-1.5%$0.067$0.068$0.066681,432
$0.068+0.001+1.5%$0.068$0.068$0.067840,397
$0.0670.0000.0%$0.067$0.068$0.0661,121,624
$0.067-0.005-6.9%$0.069$0.069$0.0653,559,404
$0.072-0.004-5.3%$0.077$0.077$0.071894,856
$0.076-0.001-1.3%$0.076$0.080$0.075599,958
$0.077-0.002-2.5%$0.080$0.080$0.0752,246,217

Splits

7 splits since 1996 · ASX:PTX · every price before a split is adjusted for it

DayRatioWhat
56-for-55Split
40-for-39Split
1-for-20Consolidation
1-for-10Consolidation
1.0268-for-1Split
20-for-19Split
1-for-2Consolidation
Ticker
ASX:PTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
ASX
Currency
AUD

What changed lately

Latest news

Change of Company Secretary

Oct 22, 2026

Closed $0.054 (-3.6%) on Oct 23, 2026

Results of Annual General Meeting

Oct 14, 2026

Closed $0.061 (-6.2%) on Oct 15, 2026

Chair Address and CEO AGM Presentation

Oct 13, 2026

Closed $0.065 (0.0%) on Oct 14, 2026

Change of Director's Interest Notice

Oct 5, 2026

Closed $0.065 (+1.6%) on Oct 6, 2026

Section 708A Cleansing Notice

Sep 29, 2026

Closed $0.067 (-6.9%) on Sep 30, 2026

All Prescient Therapeutics Limited news

Prescient Therapeutics Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
34 in the last 12 months · 249 in all · newest Nov 11, 2026 · oldest 2016
Decks
45 decks · latest Oct 14, 2026

Valuation

Price/book 4.4× against a median of 3.0×: 6th lowest of 9 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$54.09M AUD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
4.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Prescient Therapeutics Limited · ASX:PTXUS$41.64MUS$35.80Mn/an/an/a4.4×n/a0.0×n/a
Spero Therapeutics, Inc. · NASDAQ:SPROUS$43.23M−US$63.10Mn/a−1.5×n/a55.4×−71.0%2.0×1.68
Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOXUS$43.15M−US$1.28Mn/an/an/a1.1×n/a0.3×n/a
Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBPUS$42.45M−US$68.98Mn/an/an/a0.5×n/a0.1×1.85
Arecor Therapeutics PLC · LSE:ARECUS$42.37MUS$38.32M48.8×17.1×n/a8.8×38.7%0.0×n/a
OS Therapies Incorporated · AMEX:OSTXUS$42.00MUS$41.57Mn/an/an/an/an/an/a1.70
Advagene Biopharma Co., Ltd. · TPEX:6709US$41.88MUS$32.02Mn/an/an/a3.9×n/a0.0×n/a
Biomea Fusion, Inc. · NASDAQ:BMEAUS$41.75MUS$15.85Mn/an/an/a5.5×n/a0.1×1.14
Mereo BioPharma Group plc · NASDAQ:MREOUS$41.52MUS$16.00Mn/a20.0×n/a1.8×n/a0.0×1.34
Elicio Therapeutics, Inc. · NASDAQ:ELTXUS$41.05MUS$19.78Mn/an/an/a2.2×n/a0.5×1.81
MiNK Therapeutics, Inc. · NASDAQ:INKTUS$40.93MUS$33.46Mn/a167×n/an/an/an/a0.81
Median of the othersUS$41.94MUS$17.89M48.8×18.6×3.0×−16.1%0.1×1.68

Team and board

Officers

OfficerRole
James McDonnellCEO
Rebecca TunstallChief Operating Officer
Melanie LeydinCompany Secretary
Rosalind WilsonChief Medical Officer
Said SebtiScientific Founder
Upaly BahadureDirector – Clinical Affairs & Operations

Board

DirectorRole
James CampbellNon-Executive Chair
Allen EbensNon-Executive Director
Ellen FeigalNon-Executive Director
Gavin ShepherdNon-Executive Director
Melanie FarrisNon-Executive Director

Events

QuarterResultsShare move
Q4 2025Aug 20, 2025−2.3%
Q2 2025Feb 20, 2025−2.1%
Q2 2023Feb 24, 2023 · After close0.0%
Q4 2022Aug 22, 2022 · After close−2.3%
Q2 2022Feb 24, 2022−3.0%
Q4 2021Aug 30, 20210.0%
Q2 2021Feb 24, 2021−9.1%

Open Events

Decks

DeckKindSlidesDate
Shareholder Meeting (October 2026)Shareholder meeting19 slidesOct 14, 2026
Investor Presentation (August 2026)Investor deck29 slidesAug 26, 2026
Investor Presentation (April 2026)Investor deck31 slidesApr 30, 2026
Shareholder Meeting (October 2025)Shareholder meeting20 slidesOct 14, 2025
Investor Presentation (July 2025)Investor deck40 slidesJul 4, 2025
Investor Presentation (May 2025)Investor deck38 slidesMay 29, 2025
Investor Presentation (May 2025)Investor deck23 slidesMay 21, 2025
Investor Presentation (April 2025)Investor deck24 slidesApr 17, 2025
Investor Presentation (March 2025)Investor deck33 slidesMar 31, 2025
Shareholder Meeting (November 2024)Shareholder meeting33 slidesNov 14, 2024
All 45 decks
DeckKindSlidesDate
Investor Presentation (September 2024)Investor deck39 slidesSep 5, 2024
Investor Presentation (December 2023)Investor deck30 slidesDec 18, 2023
Shareholder Meeting (November 2023)Shareholder meeting46 slidesNov 16, 2023
Shareholder Meeting (November 2022)Shareholder meeting48 slidesNov 29, 2022
Investor Presentation (November 2022)Investor deck76 slidesNov 2, 2022
Investor Presentation (September 2022)Investor deck27 slidesSep 27, 2022
Investor Presentation (August 2022)Investor deck59 slidesAug 23, 2022
Technical Presentation (June 2022)Technical23 slidesJun 8, 2022
Investor Presentation (March 2022)Investor deck34 slidesMar 1, 2022
Shareholder Meeting (November 2021)Shareholder meeting51 slidesNov 12, 2021
Investor Presentation (October 2021)Investor deck36 slidesOct 13, 2021
Reach Markets 'The Insider: Meet the CEO' session (August 2021)Conference21 slidesAug 4, 2021
Shareholder Meeting (November 2020)Shareholder meeting32 slidesNov 24, 2020
Investor Presentation (May 2020)Investor deck36 slidesMay 26, 2020
Shareholder Meeting (November 2019)Shareholder meeting14 slidesNov 19, 2019
AusBiotech Conference November 2019Conference15 slidesOct 31, 2019
Finance News Network Investor Series May 2019Conference19 slidesMay 21, 2019
Investor Presentation (March 2019)Investor deck36 slidesMar 25, 2019
Emergence conference series February 2019Conference18 slidesFeb 25, 2019
Shareholder Meeting (November 2018)Shareholder meeting27 slidesNov 20, 2018
Rodman & Renshaw Global Investment Conference 2018Conference26 slidesSep 5, 2018
Investor Presentation (May 2018)Investor deck39 slidesMay 1, 2018
Investor Presentation (March 2018)Investor deck34 slidesMar 19, 2018
Shareholder Meeting (November 2017)Shareholder meeting18 slidesNov 20, 2017
Investor Presentation (October 2017)Investor deck43 slidesOct 5, 2017
Gold Coast Investment Conference 2017Conference32 slidesJun 22, 2017
Investor Presentation (May 2017)Investor deck35 slidesMay 16, 2017
29th Annual ROTH Conference 2017Conference36 slidesMar 15, 2017
Biotech Showcase, San Francisco 2017Conference35 slidesJan 11, 2017
Rodman & Renshaw 18th Annual Global Investment Conference (September 2016)Conference33 slidesSep 13, 2016
Investor Presentation (April 2016)Investor deck28 slidesApr 13, 2016
Biotech Showcase 2016Conference27 slidesJan 11, 2016
Investor Presentation (December 2015)Investor deck25 slidesDec 1, 2015
Investor Presentation (November 2015)Investor deck47 slidesNov 4, 2015
Roth Conference 2015Conference25 slidesMar 10, 2015

Open Decks

Financings

RaiseDateIn US dollars
Private placement of fully paid ordinary shares
Closed: A$1.2M raised · A$0.065 a share
Use of proceeds: Strengthen cash position and fund continued development of PTX-100 beyond the first Dose Optimisation Committee review
Sep 29, 2026US$845,261
Share purchase plan of shares
Closed: A$4.8M raised · A$0.065 a share
Use of proceeds: Strengthen cash position and fund continued development of PTX-100 beyond the first Dose Optimisation Committee review
Sep 23, 2026US$3.38M
Share purchase plan of securities under the SPP
Terms changed: share purchase plan
Sep 15, 2026
Share purchase plan of new fully paid ordinary shares
Update: up to A$7M · A$0.065 a share · Reach Markets Pty Ltd
Dealers: Reach Markets Pty Ltd (lead)
Insiders: All eligible directors have participated in the SPP
Use of proceeds: Advance PTX-100 beyond the Dose Optimisation Committee meeting expected in December 2026
Sep 14, 2026US$5.04M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue4.36M3.71M2.43M1.89M1.19M1.03M72.1K939.8K166.2K
Cost of revenue110.3K7172.09K1.40K4749041.34K1.47K605
Gross profit-110.3K4.36M3.71M2.43M1.89M1.19M1.03M1.65M938.3K1.22M
Research and development5.28M6.72M6.97M6.22M3.40M2.50M2.76M3.68M2.06M2.43M
Selling, general and administrative5.31M1.46M1.49M1.35M1.11M961.5K1.13M1.86M929.4K1.33M
Operating income-10.6M-7.54M-7.19M-9.89M-7.10M-5.43M-4.49M-3.79M-3.61M-3.76M
Depreciation and amortization110.3K5.30K7172.09K1.40K4749041.34K1.47K605
EBITDA-10.5M-7.53M-7.19M-9.88M-7.10M-5.43M-4.49M-3.79M-3.60M-3.76M
Interest expense10.7K6.53K10.6K4.19K3.30K2.20K0
Income before tax-10.4M-7.32M-11.9M-9.37M-6.87M-4.15M-4.35M-3.80M-3.51M-2.57M
Income tax-3.44M-4.36M-3.71M-2.37M-1.75M-1.19M-1.03M-1.63M-940.0K-1.06M
Net income-7.00M-7.32M-8.24M-7.00M-5.12M-4.15M-3.32M-3.80M-2.57M-2.57M
Earnings per share, basic-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.02-0.01-0.01

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents9.03M6.91M10.5M5.90M12.3M16.1M7.36M9.64M5.49M7.65M
Short-term investments20.0K20.0K4.02M16.0M20.0K20.0K20.0K20.0K20.0K20.0K
Receivables3.70M264.3K3.92M2.58M1.72M1.24M1.06M1.75M939.2K1.06M
Inventory246.3K11267.7K111
Current assets14.0M12.9M18.7M24.7M14.2M17.6M8.71M11.6M6.62M8.86M
Property, plant and equipment7.40K2.10K2.82K4.90K1.88K389422.28K2.23K
Total assets16.3M14.6M20.4M28.1M17.6M21.0M12.1M15.0M9.99M12.2M
Accounts payable902.0K3.04M1.72M1.78M505.3K232.6K479.9K393.2K243.2K340.8K
Current liabilities1.96M3.16M2.32M2.03M809.1K514.7K864.2K668.0K543.8K440.6K
Total debt223.0K330.5K165.8K156.9K156.9K56.0K
Total liabilities2.08M3.17M2.33M2.03M856.0K539.7K884.0K685.8K551.6K444.9K
Shareholders' equity14.2M11.4M18.1M26.1M16.8M20.4M11.2M14.3M9.44M11.8M
Shares outstanding1.03B805.3M805.3M727.5M647.8M611.8M394.3M244.5M215.2M213.8M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-7.22M-7.24M-7.40M-6.19M-4.31M-3.97M-2.32M-4.20M-2.15M-3.28M
Capital spending00-30-4.43K-2.31K-2.31K-2.31K-1.52K-1.69K
Free cash flow-7.22M-7.24M-7.40M-6.19M-4.32M-3.97M-2.32M-4.20M-2.15M-3.28M
Cash from investing4.00M12.0M-16.0M-4.43K-2.31K-2.31K-2.31K-1.52K-21.7K
Cash from financing9.34M-330.5K18.1K15.8M428.3K12.7M12.7M8.37M-6351.22M
Dividends paid-12.7M-7.67M-2.47K
Share buybacks-683.2K018.1K16.5M594.1K-836.6K-836.6K-699.5K-1.84K-134.5K
Change in cash2.12M-3.59M4.60M-6.37M-3.83M8.74M-2.30M4.15M-2.16M-2.11M

Open Financials

Filings

FilingDateTypeFiled with
Prescient receives $3.4 million R&D Tax RefundNov 11, 2026FinancingASX
Notification of cessation of securities - PTXNov 8, 2026FinancingASX
Change of Company SecretaryOct 22, 2026Management or board changeASX
Results of Annual General MeetingOct 14, 2026Meeting outcomeASX
Chair Address and CEO AGM PresentationOct 13, 2026Meeting outcomeASX
September 2026 Quarterly Update and Appendix 4COct 12, 2026Quarterly reportASX
Change of Director's Interest NoticeOct 5, 2026Ownership change noticeASX
Change of Director's Interest NoticeOct 5, 2026Ownership change noticeASX
Change of Director's Interest NoticeOct 5, 2026Ownership change noticeASX
Notification regarding unquoted securities - PTXSep 29, 2026Other filingsASX
Show 200 filings
FilingDateTypeFiled with
Section 708A Cleansing NoticeSep 29, 2026FinancingASX
Application for quotation of securities - PTXSep 29, 2026FinancingASX
Application for quotation of securities - PTXSep 29, 2026FinancingASX
PTX Successfully Completes $6m Raise Via SPP and PlacementSep 22, 2026FinancingASX
Proposed issue of securities - PTXSep 22, 2026FinancingASX
Trading HaltSep 20, 2026Trading halt or suspensionASX
Update - Proposed issue of securities - PTXSep 14, 2026FinancingASX
Prescient Therapeutics - Extension of Share Purchase PlanSep 14, 2026FinancingASX
Notice of Annual General Meeting/Proxy FormSep 13, 2026Meeting noticeASX
Update - Proposed issue of securities - PTXSep 7, 2026FinancingASX
Prescient Therapeutics - Extension of Share Purchase PlanSep 7, 2026FinancingASX
PTX-100 CTCL Phase 2a study reaches review milestoneSep 2, 2026Other filingsASX
Prescient Share Purchase Plan Investor PresentationAug 25, 2026FinancingASX
Prescient Therapeutics Opens SPP to Raise $7m TodayAug 25, 2026FinancingASX
Share Purchase Plan Cleansing NoticeAug 25, 2026FinancingASX
Proposed issue of securities - PTXAug 25, 2026FinancingASX
Prescient Therapeutics Launches Share Purchase Plan for $7mAug 24, 2026FinancingASX
Appendix 4E and 2026 Annual ReportAug 20, 2026Annual reportASX
Appendix 4G and Corporate Governance StatementAug 20, 2026Other filingsASX
June 2026 Quarterly Update and Appendix 4CJul 26, 2026Quarterly reportASX
March 2026 Quarterly Update and Appendix 4CApr 29, 2026Quarterly reportASX
Appendix 4D and Half Year Financial ReportFeb 24, 2026Interim reportASX
December 2025 Quarterly Update and Appendix 4CJan 29, 2026Quarterly reportASX
PTX secures EU Authorisation to commence PTX-100 TrialDec 14, 2025Other filingsASX
PTX secures EU Orphan Drug Designation for PTX-100 in CTCLNov 18, 2025Other filingsASX
September Quarterly Updated and Appendix 4COct 9, 2025Quarterly reportASX
Appendix 4E and 2025 Annual ReportAug 20, 2025Annual reportASX
Prescient successfully completes $3 million PlacementJul 31, 2025FinancingASX
June 2025 Quarterly Update and Appendix 4CJul 30, 2025Quarterly reportASX
Prescient announces results of SPP & Launches PlacementJul 29, 2025ResultsASX
Trading HaltJul 28, 2025Trading halt or suspensionASX
Prescient Therapeutics - Extension of Share Purchase PlanJul 22, 2025FinancingASX
PTX Opens First U.S. Site for PTX-100 Phase 2a TrialJul 15, 2025Operations updateASX
Prescient Therapeutics Extends Share Purchase PlanJul 14, 2025FinancingASX
Prescient Therapeutics Opens Share Purchase PlanJul 1, 2025FinancingASX
Prescient Therapeutics Launches Share Purchase Plan for $7mJun 30, 2025FinancingASX
First Patient dosed for PTX-100 Phase 2a StudyMay 26, 2025Other filingsASX
March 2025 Quarterly Update and Appendix 4CApr 28, 2025Quarterly reportASX
PTX-100 receives U.S. FDA Fast Track DesignationApr 15, 2025Other filingsASX
PTX Opens First Clinical site for PTX-100 Phase 2a StudyMar 25, 2025Other filingsASX
December 2024 Quarterly Update and Appendix 4C - amendedJan 31, 2025Quarterly reportASX
December 2024 Quarterly Update and Appendix 4CJan 30, 2025Quarterly reportASX
US FDA allows PTX-100 Ph2 trialDec 22, 2024Other filingsASX
Appointment of Chief Executive OfficerDec 17, 2024Management or board changeASX
September 2024 Quarterly Update and Appendix 4COct 30, 2024Quarterly reportASX
Prescient CEO to step down in early 2025Sep 11, 2024Management or board changeASX
Appendix 4E and 2024 Annual ReportAug 26, 2024Annual reportASX
June 2024 Quarterly Update and Appendix 4CJul 31, 2024Quarterly reportASX
March 2024 Quarterly Update and Appendix 4CApr 30, 2024Quarterly reportASX
December 2023 Quarterly Update and Appendix 4CJan 31, 2024Quarterly reportASX
PTX-100 Ph1b results show excellent safety & efficacy in TCLDec 10, 2023ResultsASX
September 2023 Quarterly Update and Appendix 4COct 30, 2023Quarterly reportASX
Appendix 4E and 2023 Annual ReportAug 24, 2023Annual reportASX
June 2023 Quarterly Update and Appendix 4CJul 26, 2023Quarterly reportASX
March 2023 Quarterly Update and Appendix 4CApr 27, 2023Quarterly reportASX
Continued promising results in PTX-100 TCL trialMar 15, 2023Other filingsASX
FDA grants broader orphan drug status to PTX100 for TCLsMar 8, 2023Other filingsASX
December 2022 Quarterly Update and Appendix 4CJan 25, 2023Quarterly reportASX
AGM PresentationNov 29, 2022Other filingsASX
September 2022 Quarterly Update and Appendix 4COct 30, 2022Quarterly reportASX
PTX-100 Trial UpdateOct 24, 2022Other filingsASX
Placement ResultsOct 10, 2022FinancingASX
SPP Results and PlacementOct 6, 2022FinancingASX
PTX unveils CellPryme-A to boost CAR-T performanceSep 22, 2022Other filingsASX
PTX strategic collaboration with MD Anderson Cancer CenterSep 6, 2022Other filingsASX
Prescient Therapeutics Launches Share Purchase PlanAug 24, 2022FinancingASX
Appendix 4E and 2022 Annual ReportAug 23, 2022Annual reportASX
PTX agreement with Thermo Fisher for scalable OmniCARAug 17, 2022Other filingsASX
PTX OmniCAR cell manufacturing contract for clinical trialsAug 15, 2022Other filingsASX
June 2022 Quarterly Update and Appendix 4CJul 24, 2022Quarterly reportASX
US FDA Grants Orphan Drug Designation to PTX-100 for PTCLJul 14, 2022Other filingsASX
Key OmniCAR Patent Granted in USJul 4, 2022Other filingsASX
PTX CellPryme-M presentationJun 7, 2022Other filingsASX
PTX unveils new clinic-ready CAR-T enhancement platformJun 7, 2022Other filingsASX
PTX-200 AML expansion after another complete responseMay 9, 2022Other filingsASX
March 2022 Quarterly Update and Appendix 4CApr 28, 2022Quarterly reportASX
Recruitment Open for Expansion Cohort of Phase 1B StudyApr 5, 2022Other filingsASX
December 2021 Quarterly Update and Appendix 4CJan 30, 2022Quarterly reportASX
September 2021 Quarterly Activities and Appendix 4COct 27, 2021Quarterly reportASX
Investor Presentation - October 2021Oct 12, 2021Other filingsASX
PTX data demonstrates key OmniCAR features in next gen CAR-TOct 12, 2021Other filingsASX
Appendix 4E and 2021 Annual ReportAug 30, 2021Annual reportASX
June 2021 Quarterly Activities and Appendix 4CJul 29, 2021Quarterly reportASX
PTX-100 trial advances following successful Phase 1bJul 26, 2021Other filingsASX
PTX successful immunogenicity testing of OmniCARJul 4, 2021Other filingsASX
PTX Completes CAR-T Manufacturing Milestone for OmniCARJun 23, 2021Other filingsASX
Response to ASX Price QueryJun 3, 2021Explanation requestASX
PTX signs CAR-T agreement with Peter MacCallumMay 10, 2021Other filingsASX
March 2021 Quarterly Update and Appendix 4CApr 29, 2021Quarterly reportASX
PTX-200 AML Trial Progresses to Higher DoseApr 22, 2021Other filingsASX
December 2020 Quarterly Update and Appendix 4CJan 27, 2021Quarterly reportASX
PTX announces 3 next-gen CAR-T programs with OmniCARJan 17, 2021Other filingsASX
Prescient Receives $1.03m R&D Tax RebateNov 10, 2020Other filingsASX
September 2020 Quarterly Update and Appendix 4COct 19, 2020Quarterly reportASX
Response to ASX QuerySep 16, 2020Explanation requestASX
PTX Raises $7 million via Strongly Supported PlacementAug 25, 2020FinancingASX
Appendix 4E and 2020 Annual ReportAug 25, 2020Annual reportASX
Successful SPP Closed EarlyAug 18, 2020Other filingsASX
Extension of Share Purchase PlanAug 14, 2020FinancingASX
PTX Announces Cell Therapy Collaboration with Peter MacAug 13, 2020Other filingsASX
PTX-100 progresses to next cohort in basket clinical studyAug 11, 2020Other filingsASX
PTX-200 AML Trial Progresses to Next Dose LevelAug 3, 2020Other filingsASX
June 2020 Quarterly Update and Appendix 4CJul 21, 2020Quarterly reportASX
2 PTX Assets Chosen in Doherty Institute COVID-19 ProgramJul 21, 2020Other filingsASX
Trading PauseJul 20, 2020Other filingsASX
Reinstatement to Official QuotationMay 25, 2020Trading halt or suspensionASX
PTX signs next-gen anti-cancer platform from Penn & OxfordMay 25, 2020Other filingsASX
Voluntary SuspensionMay 25, 2020Trading halt or suspensionASX
Pause in TradingMay 21, 2020Trading halt or suspensionASX
PTX-100 progresses to new dose, adds new siteApr 21, 2020Other filingsASX
March 2020 Quarterly Update and Appendix 4CApr 15, 2020Quarterly reportASX
December 2019 Appendix 4C - QuarterlyJan 31, 2020Quarterly reportASX
PTX-200 High Overall Response in Ph2a Breast Cancer trialDec 22, 2019Other filingsASX
Encouraging data from PTX-200 ovarian cancer trialDec 11, 2019Other filingsASX
Third complete response in PTX-200 AML TrialNov 26, 2019Other filingsASX
PTX in new CAR-T collaborationNov 17, 2019Other filingsASX
1st patient dosed in trial for first in class drug PTX-100Nov 13, 2019Other filingsASX
Receipt of R&D Tax RebateNov 7, 2019Other filingsASX
Prescient Ausbiotech Ras PresentationOct 30, 2019Other filingsASX
September 2019 Appendix 4C - QuarterlyOct 29, 2019Quarterly reportASX
Appendix 4E and 2019 Annual ReportAug 25, 2019Annual reportASX
June 2019 Appendix 4C - QuarterlyJul 23, 2019Quarterly reportASX
PTX Initiates Phase 1b Clinical Trial for PTX-100Jul 10, 2019Other filingsASX
Change to Exercise Price of OptionsMay 30, 2019Other filingsASX
Canadian Patent Granted for PTX-200May 15, 2019Other filingsASX
Entitlement Offer Results and Shortfall NotificationApr 26, 2019FinancingASX
March 2019 Appendix 4C - QuarterlyApr 24, 2019Quarterly reportASX
Despatch of Entitlement Offer DocumentsApr 3, 2019FinancingASX
ProspectusMar 24, 2019Offer documentASX
Capital Raising Presentation - March 2019Mar 24, 2019FinancingASX
Prescient Completes Equity Raising to Raise $9.1 MillionMar 24, 2019Other filingsASX
December 2018 Appendix 4C - QuarterlyJan 31, 2019Quarterly reportASX
Interim Durability Analysis of PTX-200 Breast Cancer StudyDec 9, 2018Other filingsASX
September 2018 Appendix 4C - QuarterlyOct 31, 2018Quarterly reportASX
Pipeline Collaboration for Next Generation FormulationsOct 16, 2018Other filingsASX
Change of Registry Address: Automic P/L - Sydney OfficeSep 28, 2018Other filingsASX
Improved manufacturing route for PTX-100Sep 2, 2018Other filingsASX
Appendix 4E and 2018 Annual ReportAug 31, 2018Annual reportASX
PTX-200 AML Study ExpandedAug 29, 2018Other filingsASX
June 2018 Appendix 4C - QuarterlyJul 31, 2018Quarterly reportASX
US Patent Granted for PTX-200 for Ovarian Cancer TreatmentJul 25, 2018Other filingsASX
March 2018 Appendix 4C - QuarterlyApr 23, 2018Quarterly reportASX
Response to Aware QueryApr 11, 2018Other filingsASX
PTX-200 Phase 1b Breast Cancer Trial ResultsApr 9, 2018Other filingsASX
March 2018 Investor PresentationMar 18, 2018Other filingsASX
December 2017 Appendix 4C - QuarterlyJan 31, 2018Quarterly reportASX
Clinical Trial UpdatesJan 28, 2018Other filingsASX
Clinical Hold Lifted on PTX-200 Breast Cancer TrialDec 10, 2017Other filingsASX
PTX to resume Clinical Trial of PTX-200 in Ovarian CancerNov 5, 2017Other filingsASX
September 2017 Appendix 4C - QuarterlyOct 26, 2017Quarterly reportASX
PTX-100 to Re-enter Trials in Hematology NicheOct 2, 2017Other filingsASX
Prescient to resume AML trialSep 3, 2017Other filingsASX
Appendix 4E and 2017 Annual ReportAug 29, 2017Annual reportASX
June 2017 Appendix 4C - QuarterlyJul 25, 2017Quarterly reportASX
Novel PTX-100 Cancer Approach Published in NatureJun 18, 2017Other filingsASX
Clinical Trial UpdateMay 28, 2017Other filingsASX
PTX Broker PresentationMay 16, 2017Other filingsASX
European Patent Granted for PTX-200May 11, 2017Other filingsASX
Kansas University Joins PTXs AML TrialMay 7, 2017Other filingsASX
FDA Grants Orphan Drug Designation for PTX-200 in AMLApr 30, 2017Other filingsASX
March 2017 Appendix 4C - QuarterlyApr 27, 2017Quarterly reportASX
Successful Completion of Phase 1b Breast Cancer TrialApr 6, 2017Other filingsASX
Three Additional US Patents GrantedMar 15, 2017Other filingsASX
First Cohort Successfully Completed in Phase 1b/2 AML TrialMar 7, 2017Other filingsASX
December 2016 Appendix 4C - QuarterlyJan 24, 2017Quarterly reportASX
First Patient Dosed on Phase 1b/2 AML TrialDec 13, 2016Other filingsASX
Phase 1b/2 Ovarian Trial Commences 2nd Dose EscalationDec 8, 2016Other filingsASX
September 2016 Appendix 4C - QuarterlyOct 28, 2016Quarterly reportASX
First patient at Moffitt dosed in Phase 1b/2 breast trialSep 26, 2016Other filingsASX
Appendix 4E and 2016 Annual ReportAug 31, 2016Annual reportASX
USPTO Grants Allowances for Two PTX-200 PatentsAug 4, 2016Other filingsASX
Change to exercise price of optionsJul 20, 2016Other filingsASX
June 2016 Appendix 4C - QuarterlyJul 19, 2016Quarterly reportASX
Yale Joins PTXs Phase 1b/2 AML Clinical TrialJun 15, 2016Other filingsASX
Replacement Entitlement Offer ProspectusJun 3, 2016FinancingASX
Offer DocumentMay 18, 2016Offer documentASX
PTX Secures $7.0M Capital RaisingMay 17, 2016FinancingASX
March 2016 Appendix 4C - QuarterlyApr 21, 2016Quarterly reportASX
Executive Management ChangeMar 30, 2016Other filingsASX
Virax Rights Offer Documentation - 25 May 2011Mar 30, 2016Offer documentASX
Appendix 4D (31 Dec 2010) - 25 February 2011Mar 30, 2016Interim reportASX
Exclusive License with Transgene for Novel Skin Cancer ImmunMar 30, 2016Other filingsASX
Terms Sheet - Skin CancerMar 30, 2016Other filingsASX
Appendix 4EMar 30, 2016ResultsASX
VIR201 HIV Vaccine published in AIDS JournalMar 30, 2016Other filingsASX
Update on VIR201 HIV Vaccine Clinical TrialMar 30, 2016Other filingsASX
Dutchess Continuous Investment Agreement - 10 January 2012Mar 30, 2016Other filingsASX
Suspension from Official Quotation - VHLGMar 30, 2016Trading halt or suspensionASX
TG1042 Batch Manufacturing Completed - 26 July 2011Mar 30, 2016Other filingsASX
Rights Offer - 19 July 2011Mar 30, 2016Other filingsASX

This page holds 200 of 249 filings. Open Filings

Open Filings

Cap table

Built by 6ix from Prescient Therapeutics Limited’s releases · as of Sep 29, 2026

Common shares
1,143,849,969
Fully diluted
1,143,849,969

Fully diluted

LineSharesAs of
Common shares1,143,849,969Sep 29, 2026

Share count over time

CountShares
Sep 29, 20261,143,849,969

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Allen EbensNon-Executive Director · Since at least Nov 4, 2026
Ellen FeigalNon-Executive Director · Since at least Nov 5, 2026
Gavin ShepherdNon-Executive Director · Since at least Nov 5, 2026
James CampbellNon-Executive Chair · Since at least Oct 13, 2026
James McDonnellCEO · Since at least Aug 25, 2026
Melanie FarrisNon-Executive Director · Since at least Nov 5, 2026
Melanie LeydinCompany Secretary · Since at least Nov 5, 2026
Rebecca TunstallChief Operating Officer · Since at least Nov 4, 2026
Rosalind WilsonChief Medical Officer · Since at least Nov 4, 2026
Said SebtiScientific Founder · Since at least Nov 4, 2026
All 11 people
PersonSeat
Upaly BahadureDirector – Clinical Affairs & Operations · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Prescient Therapeutics Limited.